Long-Term Multicenter Outcomes Show That Prosthetic (PTFE) Bypasses To Tibial And Peroneal Arteries Are Worthwhile

Hasan H Dosluoglu, Frank J Veith, Mark A Adelman, Yana Etkin,

Neal S Cayne, Karan Garg, Gregg S. Landis, Richard Neville, Enrico Ascher

Hasan H Dosluoglu, MD
Professor of Surgery,
Chief of Vascular Surgey, SUNY at Buffalo
Chief of Surgery and Vascular Surgery,
VA Western NY Healthcare System,
Buffalo NY



No financial disclosures or conflict of interest

Infrapopliteal (tibial/peroneal) PTFE bypass

- First described by Veith et al in 1978
- Many centers could not duplicate these results and Randomized Control Trial showed worse outcomes than GSV bypass
- Variety of configurations reported (vein patches, precuffed, fistula...)
- Adoption of EV interventions led to decrease of their utilization

Weith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, Towne JB, Bernhard VM, Bonier P, Flinn WR, et al. Six-year prospective manologous suphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg. 1986;3:104-14.

Infrapopliteal (tibial/peroneal) PTFE bypass

- Global Vascular Guidelines recommends to avoid using a non-autologous conduit for bypass unless there is no endovascular option and no adequate autologous vein.
- · Long term and ultra-long term outcomes not adequately reported for tibial bypass with PTFE; benefit remains questionable

Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S-125S.e40.

- Present patients who had long-term and ultra-long term patency from five centers using tibial PTFE bypasses over an
- Present outcomes in all patients who had tibial/peroneal bypass with PTFE in two of these five centers with complete follow-up in an attempt to put this experience into perspective

Methods

- Five Centers :
 MONTEFIORE Veith

 - INOVA Neville NORTHWELL Etkin, Landis
 - NYU Cayne, Ascher, Adelman, Veith
 BUFFALO Dosluoglu
- 2001-2018
- CLTI (Rutherford 4-6)
- Remained patent at least 48 months
- No endovascular or autologous vein options

Methods

- Two Centers
- 2001-2021 (Buffalo);2014-2022 (Northwell Health)
- CLTI (Rutherford 4-6)
- All patients who had tibial level bypass with PTFE
- Complete follow-up
- Patency, Limb salvage, Survival

Results: Five Centers


- 35 patients
- Average age 73.1±9.5 (range 53-88).
- Inflow vessels
 - 27 (77%) common femoral


 - 7 (20%) iliac 1 (3%) superficial femoral artery
- Outflow vessels

 - 15 (43%) peroneal 12 (34%) posterior tibial or medial plantar,
 - 8 (23%) anterior tibial arteries

Results: Five Centers


- A distal anastomotic vein patch 20 (57%)
- Direct anastomosis 15 (43%).
- Bypass patency 4 to 13 years (mean 5.9±2.4 years)
- 40% of bypasses required revisions for failing or failed bypass grafts during follow up








Two Centers(N=110) Buffalo: 61 Northport: 49 • Mean Age: 72.2±10.9 • 61% DM, 60% CAD, 20% COPD • 77% Tissue loss, 23% ischemic rest pain • 41% (45/110) had previous revascularizations


PTFE tibial bypass (N=110) Distal targets peroneal in 44 (40%) posterior tibial 42 (38%) anterior tibial 24 (22%) Standard PTFE graft 39 (24 precuffed, one Linton patch) Heparin-bonded PTFE graft 71 patients (42 Linton patch)

















Conclusions:

- PTFE remains a worthwhile bypass conduit for patients with CLTI to avoid major amputation
- Reasonable long-term patency and limb salvage rates, some patients acquiring benefit for even extended periods of time.
- These conduits should continue to remain in every vascular surgeon's therapeutic armamentarium and should be strongly considered in their limb salvage treatment algorithms.

